Discover the strengths & weaknesses of healthcare giants Johnson & Johnson and Pfizer. Find out which stock is more promising ...

Data360's Fingerprint solution is proprietary technology that identifies intent and maps it to digital identity to enrich HCP ... the positive Phase III WAYPOINT trial showed AstraZeneca and Amgen's ...

Oppenheimer reiterates a Perform rating on Cartesian Therapeutics (RNAC) without a price target following the company’s Q4 report. The ...

Regeneron Pharmaceuticals (REGN) appealed a decision of the United States District Court for the Northern District of West Virginia denying ...

Investors with a lot of money to spend have taken a bearish stance on Amgen AMGN. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

Ratings for Amgen AMGN were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview of their recent ...

In early February, Amgen released financial results for the 4th quarter of 2024, which I was eagerly awaiting. In addition to demonstrating efficacy in the treatment of nasal polyps in Phase 3 ...

THOUSAND OAKS, Calif., Feb. 14, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at Citi's 2025 Virtual Oncology Leadership Summit at 3:00 p.m. ET on Wednesday, Feb. 19, 2025. Jean-Charles ...

Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen ...